Table 1 Patient, donor, and graft... | American Society of Hematology

Table 1

Patient, donor, and graft characteristics

Patient					Donor	HLA mismatches*		Infused cell doses ×10⁶/kg
UPN	Age	Sex	Disease	Status†	Donor	GVH	HVG	CD34⁺	CD3⁺	CD4⁺	CD8⁺
001	4	F	B-ALL	CR2	Mother	4	4	6.5	55	41	18
002	26	M	DLBC	PD	Half-brother	1	2	2.0	17	13	07
003	6	M	T-ALL	CR2	Father	5	5	2.1	16	11	06
004	15	M	B-ALL	PD‡	Sister	4	4	2.3	32	21	10
005	7	F	AML	PD‡	Father	4	4	NE§	26	10	09
006	23	M	T-NHL	PD	Mother	4	4	1.3	12	04	07
007	7	F	B-ALL	CR2	Mother	3	3	1.3	12	09	02
008	20	F	T-ALL	CR3	Father	3	3	3.7	52	28	20
009	12	M	AML	PD‡	Father	4	4	1.8	42	16	10
010	1.5	F	AMT	N/A	Sister	2	2	3.9	20	11	07
011	0.5	F	AML	PD‡	Father	4	3	6.0	47	22	22
012	16	M	T-ALL	PD‡	Father	4	4	NE§	31	16	10
013	4	F	SCN	N/A	Mother	4	4	6.3	66	27	37
014	19	M	B-ALL	PD	Half-brother	4	4	NE§	23	14	11
015	45	F	B-ALL	CR2	Brother	2	2	1.4	20	15	08
016	50	F	AML	PD	Son	3	2	3.5	48	32	23
017	6	F	AML	PD	Father	2	2	NE§	34	19	2.4
018	42	M	MDS	PD	Sister	2	2	1.9	15	08	09
019	16	F	AML	PD	Mother	4	3	1.1	07	04	02
020	12	F	B-ALL	PD	Brother	4	5	4.2	129	18	95
021	6	M	AMT	N/A	Father	2	3	3.1	68	35	31
022	6	F	B-ALL	PD	Father	4	4	12.3	11	12	31
023	4	M	B-ALL	CR2	Father	4	4	3.8	21	18	12
024	4	F	B-ALL	CR2	Father	4	4	9.8	43	24	13
Median cell doses								3.5	29	16	11

Patient					Donor	HLA mismatches*		Infused cell doses ×10⁶/kg
UPN	Age	Sex	Disease	Status†	Donor	GVH	HVG	CD34⁺	CD3⁺	CD4⁺	CD8⁺
001	4	F	B-ALL	CR2	Mother	4	4	6.5	55	41	18
002	26	M	DLBC	PD	Half-brother	1	2	2.0	17	13	07
003	6	M	T-ALL	CR2	Father	5	5	2.1	16	11	06
004	15	M	B-ALL	PD‡	Sister	4	4	2.3	32	21	10
005	7	F	AML	PD‡	Father	4	4	NE§	26	10	09
006	23	M	T-NHL	PD	Mother	4	4	1.3	12	04	07
007	7	F	B-ALL	CR2	Mother	3	3	1.3	12	09	02
008	20	F	T-ALL	CR3	Father	3	3	3.7	52	28	20
009	12	M	AML	PD‡	Father	4	4	1.8	42	16	10
010	1.5	F	AMT	N/A	Sister	2	2	3.9	20	11	07
011	0.5	F	AML	PD‡	Father	4	3	6.0	47	22	22
012	16	M	T-ALL	PD‡	Father	4	4	NE§	31	16	10
013	4	F	SCN	N/A	Mother	4	4	6.3	66	27	37
014	19	M	B-ALL	PD	Half-brother	4	4	NE§	23	14	11
015	45	F	B-ALL	CR2	Brother	2	2	1.4	20	15	08
016	50	F	AML	PD	Son	3	2	3.5	48	32	23
017	6	F	AML	PD	Father	2	2	NE§	34	19	2.4
018	42	M	MDS	PD	Sister	2	2	1.9	15	08	09
019	16	F	AML	PD	Mother	4	3	1.1	07	04	02
020	12	F	B-ALL	PD	Brother	4	5	4.2	129	18	95
021	6	M	AMT	N/A	Father	2	3	3.1	68	35	31
022	6	F	B-ALL	PD	Father	4	4	12.3	11	12	31
023	4	M	B-ALL	CR2	Father	4	4	3.8	21	18	12
024	4	F	B-ALL	CR2	Father	4	4	9.8	43	24	13
Median cell doses								3.5	29	16	11

UPN indicates unique patient number; HVG, host-versus-graft; GVH, graft-versus-host; F, female; M, male; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; DLBC diffuse large B-cell non-Hodgkin lymphoma; SCN, severe congenital neutropenia: MDS, myelodysplastic syndrome; AMT, amegakaryocytic thrombocytopenia; CR, complete remission; PD, progressive disease; N/A, not assessable; NE, Nonevaluable.

Number of mismatches between donor and recipient at A, B, Cw (where known), DR, and DQ loci at serologic typing level.

†

Disease status summary: 7/21 CR, 14/21 PD, 3 N/A (BM failure patients).

‡

Patients who had failed to attain remission with induction therapy.

Peripheral blood leukaphereses of UPN 005, 012, 014, and 017 were contaminated with CD34⁺ leukemic blasts rendering infused CD34⁺ cell count determination nonevaluable.

View Large

This Feature Is Available To Subscribers Only